Restore Medical Ltd., a privately held medical device company developing an innovative transcatheter therapy for heart failure, announced the appointment of Chris Cleary, former Senior Vice President of Corporate Development at Medtronic, as Chairman of its Board of Directors. Restore Medical is advancing a proprietary, minimally invasive treatment aimed at patients with heart failure with reduced ejection fraction. With promising early clinical results, the company is preparing to enter the next phase of clinical development while strengthening its leadership team to support global growth and an upcoming U.S. study.
Health Technology Insights: Massive Bio Partners with ACS to Expand Cancer Trial Access
Chris Cleary brings over thirty years of leadership experience in the global healthcare and medical technology sectors. He has a distinguished track record in corporate strategy, major mergers and acquisitions, and scaling innovative companies. While at Medtronic, he played a key role in transformative deals including the $50 billion acquisition of Covidien and several significant transactions in structural heart, neuromodulation, and spine divisions.
Gilad Marom, Chief Executive Officer of Restore Medical, commented that Chris Cleary’s extensive experience, strategic insight, and dedication to advancing impactful medical innovations will be critical as the company expands its clinical programs and moves toward pivotal studies for its novel heart failure therapy. He expressed excitement in welcoming Cleary to the board, highlighting the value his leadership will bring during this important phase.
Health Technology Insights: Lifordi Immunotherapeutics Lands Investment from Sanofi Ventures
Chris Cleary, now Chairman of the Board, stated that he is thrilled to join Restore Medical at a pivotal moment. He emphasized that the company is addressing a significant unmet need in heart failure with a technology that could redefine care and improve patient outcomes. Cleary added that he looks forward to supporting the Restore team as they build a strong clinical and commercial foundation for their innovative therapy.
The appointment reflects Restore Medical’s commitment to combining cutting-edge technology with experienced leadership to advance solutions for heart failure patients. By strengthening its board with a seasoned leader like Cleary, the company aims to accelerate clinical development, expand its reach, and continue driving innovation in cardiovascular care.
Health Technology Insights: Genmab’s EPKINLY Combo Wins FDA Approval for Relapsed Follicular Lymphoma
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
